NCI-H2452

NCI-H2452/NCI-H2452细胞系/NCI-H2452细胞株/NCI-H2452人间皮瘤细胞

Cell line name NCI-H2452

Synonyms H2452; H-2452; NCIH2452

Accession CVCL_1553

Resource Identification Initiative To cite this cell line use: NCI-H2452 (RRID:CVCL_1553)

Comments Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Part of: COSMIC cell lines project.

Part of: TCGA-110-CL cell line panel.

Population: Caucasian.

Doubling time: 48 hours (PubMed=25984343).

Microsatellite instability: Stable (MSS) (Sanger).

Omics: Deep exome analysis.

Omics: Deep quantitative proteome analysis.

Omics: DNA methylation analysis.

Omics: shRNA library screening.

Omics: SNP array analysis.

Omics: Transcriptome analysis by microarray.

Omics: Transcriptome analysis by RNAseq.

Derived from site: In situ; Lung, pleura; UBERON=UBERON_0000977.

Sequence variations

Gene deletion; HGNC; 950; BAP1; Zygosity=Heterozygous (PubMed=21642991).

Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=21642991).

Mutation; HGNC; 950; BAP1; Simple; p.Ala95Asp (c.284C>A); Zygosity=Heterozygous (PubMed=21642991; PubMed=26011428).

HLA typing Source: PubMed=26589293

Class I

HLA-A A*01:01,02:01

HLA-B B*35:01,57:01

HLA-C C*04:01,06:02

Genome ancestry Source: PubMed=30894373

 

Origin % genome

African 0.27

Native American 0

East Asian, North 1.66

East Asian, South 0

South Asian 0

European, North 63.32

European, South 34.76

Disease Pleural biphasic mesothelioma (NCIt: C45665)

Pleural mesothelioma (ORDO: Orphanet_50251)

Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)

Sex of cell Male

Age at sampling Adult

Category Cancer cell line

STR profile Source(s): ATCC=CRL-5946; CLS=300391; Cosmic-CLP=908462; PubMed=25877200

 

Markers:

Amelogenin X,Y

CSF1PO 11,12

D2S1338 20

D3S1358 17

D5S818 11,12

D6S1043 11,12

D7S820 9,11

D8S1179 10

D12S391 17.3,21

D13S317 12

D16S539 11,13

D18S51 15

D19S433 13

D21S11 28,32.2

FGA 23

Penta D 9

Penta E 12,15

TH01 6,9.3

TPOX 8,11

vWA 17,18

 

Run an STR similarity search on this cell line

Publications

PubMed=7695406; DOI=10.1016/0003-4975(95)00045-M

Pass H.I., Stevens E.J., Oie H.K., Tsokos M.G., Abati A.D., Fetsch P.A., Mew D.J.Y., Pogrebniak H.W., Matthews W.J.

Characteristics of nine newly derived mesothelioma cell lines.

Ann. Thorac. Surg. 59:835-844(1995)

 

PubMed=8806092; DOI=10.1002/jcb.240630505

Phelps R.M., Johnson B.E., Ihde D.C., Gazdar A.F., Carbone D.P., McClintock P.R., Linnoila R.I., Matthews M.J., Bunn P.A. Jr., Carney D.N., Minna J.D., Mulshine J.L.

NCI-Navy Medical Oncology Branch cell line data base.

J. Cell. Biochem. Suppl. 24:32-91(1996)

 

PubMed=11030152; DOI=10.1038/sj.onc.1203815

Modi S., Kubo A., Oie H.K., Coxon A.B., Rehmatulla A., Kaye F.J.

Protein expression of the RB-related gene family and SV40 large T antigen in mesothelioma and lung cancer.

Oncogene 19:4632-4639(2000)

 

PubMed=20164919; DOI=10.1038/nature08768; PMCID=PMC3145113

Bignell G.R., Greenman C.D., Davies H.R., Butler A.P., Edkins S., Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S., Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T., Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.

Signatures of mutation and selection in the cancer genome.

Nature 463:893-898(2010)

 

PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458; PMCID=PMC2881662

Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P., Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J., Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C., Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J., Haber D.A.

A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers.

Cancer Res. 70:2158-2164(2010)

 

PubMed=21245096; DOI=10.1158/0008-5472.CAN-10-2164

Murakami H., Mizuno T., Taniguchi T., Fujii M., Ishiguro F., Fukui T., Akatsuka S., Horio Y., Hida T., Kondo Y., Toyokuni S., Osada H., Sekido Y.

LATS2 is a tumor suppressor gene of malignant mesothelioma.

Cancer Res. 71:873-883(2011)

 

PubMed=21642991; DOI=10.1038/ng.855; PMCID=PMC4643098

Bott M.J., Brevet M., Taylor B.S., Shimizu S., Ito T., Wang L., Creaney J., Lake R.A., Zakowski M.F., Reva B., Sander C., Delsite R., Powell S.N., Zhou Q., Shen R.-L., Olshen A.B., Rusch V.W., Ladanyi M.

The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21.1 losses in malignant pleural mesothelioma.

Nat. Genet. 43:668-67